Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines. The company provides livestock products, including vaccines comprising Bovishield line, Improvac/Improvest, RespiSure line, and Rispoval line; parasiticides, such as Cydectin and Dectomax; anti-infectives consisting of Aureomycin, BMD, Ceftiofur line, Draxxin, Lincomycin line, Spectramast, and Terramycin; and other products that comprise Eazi-Breed CIDR, Embrex devices, and Lutalyse. It also offers companion animal products, including vaccines comprising Vanguard 4-way Lepto and Vanguard High Titer; parasiticides, such as Revolution; anti-infectives, such as Clavamox/Synulox, Convenia, and Terramycin; and other products consisting of Rimadyl. The company markets its products directly through its sales representatives, and technical and veterinary operations specialists to livestock producers and veterinarians primarily in the United States, Europe, Africa, the Middle East, Canada, Latin America, and the Asia Pacific. Zoetis Inc. was founded in 1952 and is based in New York, New York. Zoetis Inc. is a subsidiary of Pfizer Inc.